Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes due to the lack of actionable molecular targets and the systemic toxicity associated with standard chemotherapy. Berberine chloride (BBR), a plant-derived isoquinoline alkaloid, exhibits promising anticancer activity; however, its poor solubility and limited bioavailability restrict therapeutic utility. In this study, folic acid–decorated nanoliposomes were developed to enhance the targeted delivery of BBR to TNBC cells. BBR-loaded liposomes and folic acid–functionalized liposomes were prepared using the solvent injection method and optimized through a Quality-by-Design (QbD) framework. The optimized folate-modified formulation showed a mean particle size of 168.3 nm with an entrapment efficiency of 41.8%, while non-targeted liposomes exhibited a smaller size (95.6 nm) and slightly higher drug loading (47.5%). Both systems provided sustained drug release over 72 hours, with folate-decorated liposomes demonstrating a more controlled release pattern. Cytotoxicity studies in MDA-MB-231 cells revealed significantly enhanced antiproliferative activity of folate-functionalized nanoliposomes (IC₅₀ = 24.72 μM) compared to non-targeted liposomes and free BBR. Increased intracellular reactive oxygen species generation following folate-mediated delivery suggested oxidative stress–driven cell death as a contributing mechanism. Importantly, genotoxicity evaluation using Drosophila melanogaster confirmed the safety of the liposomal formulations. Overall, folic acid–decorated nanoliposomes substantially improve the therapeutic efficacy of berberine and offer a rational, targeted nanocarrier approach for TNBC management.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: